CIVCO hires VP, launches Zonare needles

AuntMinnie.com staff writers

Oct 3, 2006

Ultrasound and radiotherapy vendor CIVCO Medical Solutions of Kalona, IA, has named Mike Marshall as vice president of engineering.

Marshall will oversee engineering and R&D functions throughout CIVCO's interventional, radiation oncology, ultrasound, and urology product lines. Marshall most recently served as technical director at electronics manufacturing services firm Celestica, based in Toronto.

In other news, the company released two new needle guidance systems for ultrasound scanners made by Zonare Medical Systems of Mountain View, CA.

The P4-1 and E9-4 needle guides are designed to work in conjunction with biopsy software on Zonare's z.one ultrasound platform.

By AuntMinnie.com staff writers
October 4, 2006

Related Reading

CIVCO debuts new Mammotome cover, September 12, 2006

CIVCO introduces intracranial transducer cover, June 15, 2006

CIVCO names radiation oncology executives, May 10, 2006

Zonare adds Washington customer, September 27, 2006

Zonare signs Montefiore, September 13, 2006

Copyright © 2006 AuntMinnie.com

Images depict a 49-year-old female participant with cryptogenic cirrhosis who presented with a 3.2-cm liver lesion. This biopsy-confirmed hepatocellular carcinoma (HCC) with an initial categorization of Liver Imaging Reporting and Data System (LI-RADS) category LR-4 (probably HCC) at CT was upgraded to LR-5 (definitely HCC) at contrast-enhanced ultrasound (CEUS). (A) Precontrast CT images in the liver show vague hypoattenuation in the medial left hepatic lobe (arrows). (B) Arterial phase images demonstrate no definite arterial phase hyperenhancement (arrows). (C) Washout and an enhancing capsule (arrows) on a late-phase image resulted in an LR-4 categorization. (D) B-mode ultrasound shows a round hypoechoic nodule (arrows). (E) An early-phase CEUS image shows clear arterial-phase hyperenhancement (arrows); (F) No washout at one minute (arrows), and (G) late, mild washout at four minutes (arrows) resulted in a CEUS LR-5 categorization.

CEUS resolves indeterminate CT, MRI liver observations

January 21, 2025

Ultrasound Portable

POCUS useful for diagnosis of retained conception tissue

January 15, 2025

Ultrasound Probe2 Social

AI guidance leads to better LUS image acquisition by novice users

January 15, 2025

Ultrasound images depict a 63-year-old man who underwent radiofrequency ablation (RFA) for the treatment of secondary hyperparathyroidism. (A–D) 2D images show four hyperplastic parathyroid glands on the right and left sides (marked with crosshairs). The numbers near the crosshairs represent the number of measured trails. (E) Ultrasound-guided infusion of isolation fluid (arrowheads) around the hyperplastic parathyroid gland to protect vital organs such as the trachea (Tr), carotid arteries (CA), and recurrent laryngeal nerve pathway area (arrow). F) Ultrasound-guided RFA of the hyperplastic parathyroid gland. (G) Immediate postoperative contrast-enhanced ultrasound shows no contrast enhancement in the ablation area. The ablation procedures for the other three parathyroid glands were the same as those described above. Image courtesy of the RSNA,

Ultrasound ablation is effective for treating hyperparathyroidism

January 7, 2025

CEUS resolves indeterminate CT, MRI liver observations

By Amerigo Allegretto

Contrast-enhanced ultrasound (CEUS) can resolve some high-risk indeterminate liver observations initially seen on CT or MRI.

January 21, 2025

Images depict a 49-year-old female participant with cryptogenic cirrhosis who presented with a 3.2-cm liver lesion. This biopsy-confirmed hepatocellular carcinoma (HCC) with an initial categorization of Liver Imaging Reporting and Data System (LI-RADS) category LR-4 (probably HCC) at CT was upgraded to LR-5 (definitely HCC) at contrast-enhanced ultrasound (CEUS). (A) Precontrast CT images in the liver show vague hypoattenuation in the medial left hepatic lobe (arrows). (B) Arterial phase images demonstrate no definite arterial phase hyperenhancement (arrows). (C) Washout and an enhancing capsule (arrows) on a late-phase image resulted in an LR-4 categorization. (D) B-mode ultrasound shows a round hypoechoic nodule (arrows). (E) An early-phase CEUS image shows clear arterial-phase hyperenhancement (arrows); (F) No washout at one minute (arrows), and (G) late, mild washout at four minutes (arrows) resulted in a CEUS LR-5 categorization.

POCUS useful for diagnosis of retained conception tissue

By Amerigo Allegretto

Point-of-care ultrasound (POCUS) can be a useful tool for diagnosing the presence of retained conception tissue.

January 15, 2025

Ultrasound Portable

AI guidance leads to better LUS image acquisition by novice users

By Amerigo Allegretto

Healthcare professionals who are not sonography experts can successfully acquire lung ultrasound (LUS) images with AI assistance.

January 15, 2025

Ultrasound Probe2 Social

Ultrasound ablation is effective for treating hyperparathyroidism

By Amerigo Allegretto

Ultrasound-guided thermal ablation techniques are safe and effective in treating patients with secondary hyperparathyroidism.

January 7, 2025

Ultrasound images depict a 63-year-old man who underwent radiofrequency ablation (RFA) for the treatment of secondary hyperparathyroidism. (A–D) 2D images show four hyperplastic parathyroid glands on the right and left sides (marked with crosshairs). The numbers near the crosshairs represent the number of measured trails. (E) Ultrasound-guided infusion of isolation fluid (arrowheads) around the hyperplastic parathyroid gland to protect vital organs such as the trachea (Tr), carotid arteries (CA), and recurrent laryngeal nerve pathway area (arrow). F) Ultrasound-guided RFA of the hyperplastic parathyroid gland. (G) Immediate postoperative contrast-enhanced ultrasound shows no contrast enhancement in the ablation area. The ablation procedures for the other three parathyroid glands were the same as those described above. Image courtesy of the RSNA,

RFA successful for treating malignant thyroid nodules

By Amerigo Allegretto

Radiofrequency ablation (RFA) can successfully treat malignant thyroid nodules with minimal adverse events.

December 13, 2024

What can we do to increase global access to imaging?

By Josh Sokol, MD

Outreach and philanthropy will be central themes at RSNA 2024. Ahead of the congress, teleradiologist Josh Sokol, MD, explains why the radiology community must work together to improve access to imaging.

December 1, 2024

The clinical team perform an ultrasound scan at the Nyankunde Hospital, the Democratic Republic of the Congo, where Warren Cooper, MD, has performed operations ranging from repairing broken bones to craniotomies for over a decade.

Inquest into neonatal death highlights ultrasound errors

A radiologist and a sonographer failed to diagnose critical conditions in two pregnant women, including a twin baby who died three days after birth, a report has revealed.

November 27, 2024

Digital Justice Scales

CEUS-based radiomics model aids in breast cancer diagnosis

By Amerigo Allegretto

A contrast-enhanced ultrasound (CEUS)-based radiomics model could help accurately diagnose breast cancer.

November 26, 2024

Ultrasound Scanner Computerized 400 (1)

Ultrasound-based deep learning models aid thyroid nodule prediction

By Amerigo Allegretto

A deep learning-based framework incorporating ultrasound images and clinical data can help in thyroid nodule prediction.

November 25, 2024

Elastography shows tissue stiffness in athletes with low-back pain

By Amerigo Allegretto

Shear-wave elastography shows tissue stiffness in athletes with low-back pain, which could help guide rehabilitation strategies.

November 22, 2024

Nomogram model predicts malignancy risk in ovarian masses

By Amerigo Allegretto

A nomogram model based on O-RADS ultrasound findings and clinical and lab indicators can predict malignancy risk in adnexal cystic-solid masses.

November 19, 2024

Ovarian Cancer Social

AI-enabled CCTA on par with IVUS for plaque quantification

By Kate Madden Yee

An AI-powered automated plaque quantification tool for coronary CT angiography (CCTA) performs on par with intravascular ultrasound (IVUS) for quantifying heart plaque volume and characterizing plaque.

November 14, 2024

Page 1 of 513